A Phase Ib/II Study of Afainib plus Nimotuzumab in Non-Small Cell Lung Cancer Patients with Acquired Resistance to Gefitinib or Erlotinib

被引：0
|
作者：
Lee, Ji Yun [1 ]
Lim, Sung Hee [1 ]
Kim, Haesu [1 ]
Yoo, Kwai Han [1 ]
Jung, Ki Sun [1 ]
Song, Haa-Na [1 ]
Kwak, Mikyong [1 ]
Han, Mijung [1 ]
Sun, Jong-Mu [1 ]
Lee, Se-Hoon [1 ]
Ahn, Jin Seok [1 ]
Park, Keunchil [1 ]
Ahn, Myung-Ju [1 ]
机构：
[1] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Med,Div Hematol Oncol, Seoul, South Korea
来源：
JOURNAL OF THORACIC ONCOLOGY | 2015年 / 10卷 / 09期
关键词：
afainib; nimotuzumab; non-small cell lung cancer; Acquired resistance;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MINI05.06
引用
收藏
页码：S277 / S278
页数：2
相关论文
共 50 条
  • [1] A Phase Ib/II Study of Afatinib in Combination with Nimotuzumab in Non-Small Cell Lung Cancer Patients with Acquired Resistance to Gefitinib or Erlotinib
    Lee, Ji Yun
    Sun, Jong-Mu
    Lim, Sung Hee
    Kim, Hae Su
    Yoo, Kwai Han
    Jung, Ki Sun
    Song, Haa-Na
    Ku, Bo Mi
    Koh, Jiae
    Bae, Yeon-Hee
    Lee, Se-Hoon
    Ahn, Jin Seok
    Park, Keunchil
    Ahn, Myung-Ju
    [J]. CLINICAL CANCER RESEARCH, 2016, 22 (09) : 2139 - 2145
  • [2] A phase Ib/II study of afatinib in combination with nimotuzumab in non-small cell lung cancer patients with acquired resistance to gefitinib or erlotinib.
    Ahn, Myung-Ju
    Lee, Ji Yun
    Sun, Jong-Mu
    Ku, Bo Mi
    Koh, Jiae
    Lim, Sung Hee
    Lee, Min-Young
    Kim, Haesu
    Ahn, Jin Seok
    Park, Keunchil
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [3] Phase II study of erlotinib for acquired resistance to gefitinib in patients with advanced non-small cell lung cancer
    Horiike, A.
    Yamamoto, N.
    Tanaka, H.
    Yanagitani, N.
    Kudo, K.
    Ohyanagi, F.
    Naito, T.
    Murakami, H.
    Horai, T.
    Nishio, M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [4] Phase II Study of Erlotinib for Acquired Resistance to Gefitinib in Patients with Advanced Non-small Cell Lung Cancer
    Horiike, Atsushi
    Yamamoto, Nobuyuki
    Tanaka, Hisashi
    Yanagitani, Noriko
    Kudo, Keita
    Ohyanagi, Fumiyoshi
    Ono, Akira
    Naito, Tateaki
    Murakami, Haruyasu
    Horai, Takeshi
    Nishio, Makoto
    [J]. ANTICANCER RESEARCH, 2014, 34 (04) : 1975 - 1981
  • [5] Characterising acquired resistance to erlotinib in non-small cell lung cancer patients
    Karachaliou, Niki
    Codony-Servat, Jordi
    Paulina Bracht, Jillian Wilhelmina
    Ito, Masaoki
    Filipska, Martyna
    Pedraz, Carlos
    Chaib, Imane
    Bertran-Alamillo, Jordi
    Felipe Cardona, Andres
    Angel Molina, Miguel
    Rosell, Rafael
    [J]. EXPERT REVIEW OF RESPIRATORY MEDICINE, 2019, 13 (10) : 1019 - 1028
  • [6] A Randomized, Phase II Study of Nimotuzumab Plus Gefitinib vs Gefitinib in Advanced Non-Small Cell Lung Cancer After Platinum-Based Chemotherapy
    Kim, Hye Ryun
    Jang, Joung Soon
    Sun, Jong-Mu
    Ahn, Myung-Ju
    Kim, Dong-Wan
    Jung, Inkyung
    Moon, Yong-Wha
    Lim, Sun Min
    Jeong, Jae Heon
    Lee, Ki Hyeong
    Kim, Joo-Hang
    Lee, Dae Ho
    Kim, Sang-We
    Cho, Byoung Chul
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S663 - S664
  • [7] A PHASE II STUDY OF ERLOTINIB FOR PATIENTS WITH ADVANCED/METASTATIC NON-SMALL CELL LUNG CANCER WHO HAD FAILED GEFITINIB
    Lee, D. H.
    Kim, H. T.
    Kim, S.
    Suh, C.
    Lee, J.
    [J]. ANNALS OF ONCOLOGY, 2008, 19 : 102 - 102
  • [8] A phase I trial of gefitinib and nimotuzumab in patients with advanced non-small cell lung cancer (NSCLC)
    Kim, Se Hyun
    Shim, Hyo Sup
    Cho, Jaeho
    Jeong, Jae Heon
    Kim, Sun Mi
    Hong, Yun Kyoung
    Sung, Ji Hee
    Ha, Sang-Jun
    Kim, Hye Ryun
    Chang, Hyun
    Kim, Joo Hang
    Tania, Crombet
    Cho, Byoung Chul
    [J]. LUNG CANCER, 2013, 79 (03) : 270 - 275
  • [9] A phase I trial of gefitinib and nimotuzumab in patients with advanced non-small cell lung cancer (NSCLC).
    Kim, Han Sang
    Cho, Byoung Chul
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [10] A phase Ib/II study of cabozantinib (XL184) with or without erlotinib in patients with non-small cell lung cancer
    Wakelee, Heather A.
    Gettinger, Scott
    Engelman, Jeffrey
    Janne, Pasi A.
    West, Howard
    Subramaniam, Deepa S.
    Leach, Joseph
    Wax, Michael
    Yaron, Yifah
    Miles, Dale R.
    Lara, Primo N., Jr.
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2017, 79 (05) : 923 - 932
12345